Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.

about

Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.

Item

http://www.wikidata.org/entity/Q51462501

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Novel sulfobutyl ether cyclode ...... osomal irinotecan formulation.

@en

Novel sulfobutyl ether cyclode ...... osomal irinotecan formulation.

@nl

type

Item

label

Novel sulfobutyl ether cyclode ...... osomal irinotecan formulation.

@en

Novel sulfobutyl ether cyclode ...... osomal irinotecan formulation.

@nl

prefLabel

Novel sulfobutyl ether cyclode ...... osomal irinotecan formulation.

@en

Novel sulfobutyl ether cyclode ...... osomal irinotecan formulation.

@nl

P1476

Novel sulfobutyl ether cyclode ...... osomal irinotecan formulation.

@en

P2093

CaiXia Wang

http://www.w3.org/2001/XMLSchema#string

ChunLei Li

http://www.w3.org/2001/XMLSchema#string

JingXia Cui

http://www.w3.org/2001/XMLSchema#string

Lan Zhang

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Na Wei

http://www.w3.org/2001/XMLSchema#string

Ping Wang

http://www.w3.org/2001/XMLSchema#string

Xian Xiu

http://www.w3.org/2001/XMLSchema#string

YanHui Li

http://www.w3.org/2001/XMLSchema#string

YongFeng Li

http://www.w3.org/2001/XMLSchema#string

P2860

Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.

Influence of sulfobutyl ether beta-cyclodextrin (Captisol) on the dissolution properties of a poorly soluble drug from extrudates prepared by hot-melt extrusion.

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.

Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.

Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan.

Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.

Irinotecan in the treatment of small cell lung cancer: a review of patient safety considerations.

A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer.

Irinotecan in the treatment of elderly patients with advanced colorectal cancer.

Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment.

P304

765-773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.2042-7158.2011.01272.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21585373

http://www.w3.org/2001/XMLSchema#string